These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Lim SM; Chang H; Yoon MJ; Hong YK; Kim H; Chung WY; Park CS; Nam KH; Kang SW; Kim MK; Kim SB; Lee SH; Kim HG; Na II; Kim YS; Choi MY; Kim JG; Park KU; Yun HJ; Kim JH; Cho BC Ann Oncol; 2013 Dec; 24(12):3089-94. PubMed ID: 24050953 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of everolimus in metastatic urothelial cancer. Smith AB; Pruthi RS BJU Int; 2013 Aug; 112(4):427-8. PubMed ID: 23879903 [No Abstract] [Full Text] [Related]
5. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597 [TBL] [Abstract][Full Text] [Related]
6. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Trédan O; Treilleux I; Wang Q; Gane N; Pissaloux D; Bonnin N; Petit T; Cretin J; Bonichon-Lamichhane N; Priou F; Lavau-Denes S; Mari V; Freyer G; Lebrun D; Alexandre J; Ray-Coquard I Target Oncol; 2013 Dec; 8(4):243-51. PubMed ID: 23238879 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Yoon DH; Ryu MH; Park YS; Lee HJ; Lee C; Ryoo BY; Lee JL; Chang HM; Kim TW; Kang YK Br J Cancer; 2012 Mar; 106(6):1039-44. PubMed ID: 22343617 [TBL] [Abstract][Full Text] [Related]
8. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Ray-Coquard I; Favier L; Weber B; Roemer-Becuwe C; Bougnoux P; Fabbro M; Floquet A; Joly F; Plantade A; Paraiso D; Pujade-Lauraine E Br J Cancer; 2013 May; 108(9):1771-7. PubMed ID: 23612453 [TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Slomovitz BM; Lu KH; Johnston T; Coleman RL; Munsell M; Broaddus RR; Walker C; Ramondetta LM; Burke TW; Gershenson DM; Wolf J Cancer; 2010 Dec; 116(23):5415-9. PubMed ID: 20681032 [TBL] [Abstract][Full Text] [Related]
10. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma. Edelman MJ; Meyers FJ; Houston J; Lauder I Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226 [TBL] [Abstract][Full Text] [Related]
12. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Wülfing C; Machiels JP; Richel DJ; Grimm MO; Treiber U; De Groot MR; Beuzeboc P; Parikh R; Pétavy F; El-Hariry IA Cancer; 2009 Jul; 115(13):2881-90. PubMed ID: 19399906 [TBL] [Abstract][Full Text] [Related]
13. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Gerullis H; Eimer C; Ecke TH; Georgas E; Freitas C; Kastenholz S; Arndt C; Heusch C; Otto T Med Oncol; 2012 Dec; 29(4):2870-6. PubMed ID: 22447503 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298 [TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. Doi T; Muro K; Boku N; Yamada Y; Nishina T; Takiuchi H; Komatsu Y; Hamamoto Y; Ohno N; Fujita Y; Robson M; Ohtsu A J Clin Oncol; 2010 Apr; 28(11):1904-10. PubMed ID: 20231677 [TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. Kim DW; Oh DY; Shin SH; Kang JH; Cho BC; Chung JS; Kim H; Park KU; Kwon JH; Han JY; Kim MJ; Bang YJ BMC Cancer; 2014 Nov; 14():795. PubMed ID: 25362970 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. Dumez H; Gallardo E; Culine S; Galceran JC; Schöffski P; Droz JP; Extremera S; Szyldergemajn S; Fléchon A Mar Drugs; 2009 Sep; 7(3):451-63. PubMed ID: 19841725 [TBL] [Abstract][Full Text] [Related]
18. Atezolizumab in invasive and metastatic urothelial carcinoma. Crist M; Balar A Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323 [TBL] [Abstract][Full Text] [Related]
19. Safety profile and treatment response of everolimus in different solid tumors: an observational study. Verzoni E; Pusceddu S; Buzzoni R; Garanzini E; Damato A; Biondani P; Testa I; Grassi P; Bajetta E; de Braud F; Procopio G Future Oncol; 2014; 10(9):1611-7. PubMed ID: 25145431 [TBL] [Abstract][Full Text] [Related]